STERIS (NYSE:STE) Announces Earnings Results

by · The Cerbat Gem

STERIS (NYSE:STE – Get Free Report) posted its quarterly earnings data on Wednesday. The medical equipment provider reported $2.14 EPS for the quarter, beating analysts’ consensus estimates of $2.11 by $0.03, Briefing.com reports. STERIS had a net margin of 8.02% and a return on equity of 13.91%. The company had revenue of $1.33 billion during the quarter, compared to analyst estimates of $1.33 billion. During the same period in the prior year, the firm earned $2.03 earnings per share. The business’s quarterly revenue was up 7.3% on a year-over-year basis. STERIS updated its FY25 guidance to $9.05-$9.25 EPS and its FY 2025 guidance to 9.050-9.250 EPS.

STERIS Price Performance

STERIS stock traded up $3.69 during mid-day trading on Friday, hitting $219.19. 1,071,783 shares of the company were exchanged, compared to its average volume of 490,598. The company has a quick ratio of 1.49, a current ratio of 2.33 and a debt-to-equity ratio of 0.35. The business has a fifty day moving average of $232.29 and a 200 day moving average of $227.64. STERIS has a 1-year low of $195.47 and a 1-year high of $248.24. The company has a market capitalization of $21.62 billion, a PE ratio of 50.03 and a beta of 0.85.

STERIS Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 19th. Investors of record on Tuesday, November 19th will be given a $0.57 dividend. The ex-dividend date of this dividend is Tuesday, November 19th. This represents a $2.28 annualized dividend and a yield of 1.04%. STERIS’s dividend payout ratio (DPR) is currently 52.05%.

Insiders Place Their Bets

In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the completion of the transaction, the chief financial officer now directly owns 42,930 shares in the company, valued at $10,603,710. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.14% of the company’s stock.

Wall Street Analyst Weigh In

STE has been the topic of a number of research reports. KeyCorp upped their target price on STERIS from $255.00 to $265.00 and gave the company an “overweight” rating in a report on Tuesday, September 3rd. Stephens reiterated an “overweight” rating and issued a $260.00 target price on shares of STERIS in a report on Thursday. Piper Sandler upgraded STERIS from a “neutral” rating to an “overweight” rating and upped their target price for the company from $230.00 to $260.00 in a report on Thursday, October 24th. JMP Securities restated a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a report on Wednesday, August 7th. Finally, StockNews.com downgraded STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 29th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $253.00.

Get Our Latest Research Report on STERIS

About STERIS

(Get Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Featured Articles